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DART  Direct analysis in real time 
DBE  Double bond equivalents 
DDA  Data-dependent acquisition 
DEA  Drug Enforcement Administration 
DESI  Desorption electrospray ionisation 
DIA  Data-independent acquisition 
DOB  4-bromo-2,5-dimethoxyamphetamine 
DOET  4-ethyl-2,5-dimethoxyamphetamine 
DOH/2,5-DMA  2,5-dimethoxyamphetamine 
DOI  4-iodo-2,5-dimethoxyamphetamine 
DOM  2,5-dimethoxy-4-methylamphetamine 
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DOT  2,5-dimethoxy-4-methylthioamphetamine 
DOX  2,5-dimethoxyamphetamines derivatives 
ECC  Extracted compound chromatogram 
EE  Even electron 
EI  Electron ionisation 
EIC  Extracted ion chromatogram 
EMCDDA  European Monitoring Centre for Drugs and Drug 
Addiction 
ESI+  Positive electrospray ionisation 
EU  European Union 
eV  Electron volt 
EWS  Early Warning System 
FbF  Find by Formula 
FIA  Flow injection analysis 
FUB-144  [1-(4-fluorobenzyl)-1H-3-indolyl](2,2,3,3-tetramethylcyclopropyl)methanone 
FUB-NPB-22  8-quinolinyl 1-(4-fluorobenzyl)-1H-indazole-3-carboxylate 
FWHM  Full width at half maximum 
GC-MS  Gas chromatography – mass spectrometry 
GHz  Gigahertz 
GUI  Graphical user interface 
H2O  Water 
HCD  Higher energy collision dissociation 
HESI  Heated electrospray ionisation 
HPLC  High-performance liquid chromatography 
HRAM  High-resolution accurate mass 
HRMS  High-resolution mass spectrometry 
Hz  Hertz 
IDA  Information-dependent acquisition 
IL  Illinois 
IS  Internal standard 
IUPAC  International Union of Pure and Applied Chemists 
JWH  John William Huffman 
JWH-007  (2-methyl-1-pentyl-1H-3-indolyl)(1-naphthyl)methanone 
JWH-015  (2-methyl-1-propyl-1H-3-indolyl)(1-naphthyl)methanone 
JWH-016  (1-butyl-2-methyl-1H-3-indolyl)(1-naphthyl)methanone 
JWH-018  1-naphthyl(1-pentyl-1H-3-indolyl)methanone 
JWH-019  (1-hexyl-1H-3-indolyl)(1-naphthyl)methanone 
JWH-020  (1-heptyl-1H-3-indolyl)(1-naphthyl)methanone 
JWH-030  1-naphthyl(1-pentyl-1H-3-pyrrolyl)methanone 
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JWH-073  (1-butyl-1H-3-indolyl)(1-naphthyl)methanone 
JWH-081  (4-methoxy-1-naphthyl)(1-pentyl-1H-3-indolyl)methanone 
JWH-098  (4-methoxy-1-naphthyl)(2-methyl-1-pentyl-1H-3-indolyl)methanone 
JWH-122  (4-methyl-1-naphthyl)(1-pentyl-1H-3-indolyl)methanone 
JWH-200  {1-[2-(4-morpholinyl)ethyl]-1H-3-indolyl}(1-naphthyl)methanone 
JWH-203  2-(2-chlorophenyl)-1-(1-pentyl-1H-3-indolyl)ethanone 
JWH-210  (4-ethyl-1-naphthyl)(1-pentyl-1H-3-indolyl)methanone 
JWH-250  2-(2-methoxyphenyl)-1-(1-pentyl-1H-3-indolyl)ethanone 
JWH-307  [5-(2-fluorophenyl)-1-pentyl-1H-3-pyrrolyl](1-naphtyl)methanone 
KMD  Kendrick mass defect 
kV  Kilovolt 
L  Litre 
LC-MS  Liquid chromatography – mass spectrometry 
LLE  Liquid-liquid extraction 
LLOQ  Lower limit of quantification 
LOD  Limit of detection 
LRMS  Low-resolution mass spectrometry 
M  Moles per litre; mol/L 
m/z  Mass-to-charge ratio 
M+   Radical cation 
M+   Diradical cation 
MA  Massachusetts 
MAE  Microwave-assisted extraction 
MALDI  Matrix-assisted laser desorption ionisation 
mDa  Millidalton 
MDF  Mass defect filtering 
MDMA  3,4-methylenedioxymethamphetamine 





MDMB-PINACA  Methyl N-[(1-pentyl-1H-3-indazolyl)carbonyl]-3-methylvalinate 
MDMC  2,3-methylenedioxymethcathinone 
MDPBP  3,4-methylenedioxy- -pyrrolidinobutiophenone 
MDPPP  3,4-methylenedioxy- -pyrrolidinopropiophenone 
MDPV  3,4-methylenedioxypyrovalerone 
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MFE  Molecular feature extraction 
MFG  Molecular formula generator 
mg  Milligram 
MI  Michigan 
mL  Millilitre 
mM  Millimoles per litre; mmol/L 
mm  Millimetre 
MMB-FUBINACA  Methyl N-{[1-(4-fluorobenzyl)-1H-3-indazolyl]carbonyl}valinate 
MO  Missouri 
MPBP  4-methyl- -pyrrodinobutiophenone 
MS  Mass spectrometry 
MS/MS or MS2  Tandem mass spectrometry 
MSC  Molecular Structure Correlator 
MSn  Multistage tandem-mass spectrometry 
M   Megaohm 
N2  Nitrogen gas 
NaCl  Sodium chloride 
ng  Nanogram 
NH3  Ammonia 
NJ  New Jersey 
NL  Neutral loss 
NLF  Neutral loss filtering 
NMI  National Measurement Institute 
NMR  Nuclear magnetic resonance 
NPS  New psychoactive substances 
NSW  New South Wales 
OE  Odd electron 
OH  Ohio 
PA  Pennsylvania 
PCA  Principal component analysis 
PCDL  Personal compound database and library 
PET  Positron emission tomography 
PFAC  Perfluoroalkyl compounds 
PiHKAL  Phenethylamines I have known and loved 
PLE  Pressurised liquid extraction 
pNLC  Precursor neutral loss chromatogram 
ppm  Parts per million 
PPP  Pyrrolidinopropiophenone 
PTR  Proton transfer reaction 
QLD  Queensland 
QqQ  Triple quadrupole 
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QTOF  Quadrupole time-of-flight 
R2  Coefficient of determination 
rpm  Revolutions per minute 
s  Seconds 
S/N  Signal-to-noise ratio 
SA  South Australia 
SALLE  Salting-out assisted liquid-liquid extraction 
SCX  Strong cation exchange 
SIEVE®  Statistical Iterative Exploratory Visualization 
Environment 
SPE  Solid-phase extraction 
SRI  Selective reagent ionisation 
STA  Systematic toxicological analysis 
SWATH®  Sequential window acquisition of all theoretical spectra  
SWGDRUG  Scientific Working Group for the Analysis of Seized 
Drugs 
TCC  Total compound chromatogram 
TCMP  Tetramethylcyclopropyl 
THC  9-tetrahydrocannabinol 
TIC  Total ion chromatogram 
TiHKAL  Tryptamines I have known and loved 
TOF  Time-of-flight 
TX  Texas 
UK  United Kingdom 
UNODC  United Nations Office of Drugs and Crime 
UR-144  (1-pentyl-1H-3-indolyl)(2,2,3,3-tetramethylcyclopropyl)methanone 
USA  United States of America 
V  Volt 
VBA  Visual Basic for Applications 
XLR-11  [1-(5-fluoropentyl)-1H-3-indolyl](2,2,3,3-tetramethylcyclopropyl)methanone 
-PVP  -pyrrolidinovalerophenone 
  Mass error 
g  Microgram 
L  Microlitre 
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Abstract 
The proliferation of new psychoactive substances (NPS) has become problematic for 
forensic drug chemistry and analytical toxicology laboratories that rely on the use of 
targeted screening methods for the detection of analytes. In order to detect novel NPS 
derivatives, non-targeted or general unknown screening workflows need to be 
implemented. Recently, high-resolution mass spectrometry (HRMS) has become the 
workhorse for general drug screening due to its ability to collect full scan MS and 
MS/MS data, which can be retrospectively interrogated and has been identified as a 
potential tool for non-targeted screening.  
Top-down screening approaches involving the selection of abundant precursor ions is 
difficult in toxicological analyses particular when analytes of interest exist at low 
concentrations. Mass defect-based top-down screening approaches were developed 
and evaluated for the detection of low concentration analogues. Application of mass 
defect filtering (MDF) on fortified and authentic samples revealed that the efficacy of 
this technique was dependent on sample complexity, chromatographic resolution and, 
more critically, software availability and/or capability. An in-house Microsoft Office 
Excel-based KMD analysis software was developed using the Visual Basic for 
Applications (VBA) programming language. Briefly, the software workflow involves 
the importation of single or multiple comma-separated value (.csv) files, followed by 
the calculation of KMD values for each mass-to-charge (m/z) entry normalized to –
CH2. The data can then be filtered by m/z range, intensity, mass defect and even/odd 
mass. KMD values which match the user-defined values (up to 8 different values can 
be monitored simultaneously) are highlighted and isolated for easy visualization. 
These m/z values can then be extracted using the corresponding native data processing 
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software to observe the presence of distinct chromatographic peaks for the selected 
m/z values. The program was capable of rapidly interrogating numerical MS data from 
multiple files acquired by major HRMS platform vendors. In addition, differential 
analysis software was also evaluated for the detection of anomalous signals not present 
in control samples, however, this technique requires representative control matrices in 
addition to supplementary data processing software that is not always provided by 
HRMS vendors or requires separate purchase. 
Bottom-up screening strategies involve the monitoring of common product ions and 
neutral losses (NLs) for particular subclasses, where aligning chromatographic peaks 
for multiple product ions or NLs may indicate the possible presence of a novel NPS 
analogue. Collision-induced dissociation (CID) studies were performed on synthetic 
cathinone, hallucinogenic phenethylamine and synthetic cannabinoid derivatives to 
determine key product ions and NLs. 2C-X and DOX derivatives had common losses 
of NH3, CH6N and C2H9N and common product ions at m/z 164.0837, 149.0603 and 
134.0732 for 2C-X derivatives and m/z 178.0994, 163.0754, 147.0804 and 135.0810 
for DOX derivatives. The 25X-NBOMe derivatives had characteristic product ion 
spectra with abundant ions at m/z 121.0654 and 91.0548, together with minor NLs 
corresponding to 2-methylanisole and 2-methoxybenzylamine and C9H14NO.  
Product ion pairs m/z 117.0573/105.0699, 131.0730/105.0699, 145.0886/119.0855, 
159.1043/133.1012 149.0635/123.0605 and 161.0835/135.0804 were indicative of 
different substituted traditional cathinone derivatives. Methylenedioxycathinone-type 
cathinones did not exhibit common product ions but instead exhibited NLs of 18.0106 
(H2O), 48.0211 (CH4O2) and 76.0160 Da (C2H4O3). The presence of m/z 98.0964, 
112.1121 or 126.1277 and a NL of 71.0735 Da was indicative of synthetic cathinones 
that contain a pyrrolidine ring such as the -pyrrolidinophenone-type and 
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methylenedioxy- -pyrrolidinophenone-type cathinones. Product ions m/z 105.0699 
and 119.0855 were indicative of unsubstituted and methylphenyl -
pyrrolidinophenone-type cathinones, respectively. While m/z 149.0233 was indicative 
of methylenedioxy- -pyrrolidinophenone-type cathinones. 
Naphthoylindole derived synthetic cannabinoids exhibited major product ions at m/z 
155.0491, 169.0648, 183.0804 and m/z 185.0597 while 2-iodobenzoylindole and 
TMCP derivatives exhibited the product ion m/z 230.9301 and m/z 125.0961, 
respectively. Product ions corresponding to the linker-core-tail were observed at m/z 
214.1226 (PICA), 232.1132 (5F-PICA), 215.1179 (PINACA), 233.1085 (5F-
PINACA), 240.1383 (CHMICA), 241.1335 (CHMINACA), 252.0819 (FUBICA) and 
253.0772 (FUBINACA). Furthermore, the presence of m/z 144.0444, 158.0600 and 
145.0402 were indicative of the indole, 2-methylindole and indazole acylium cations. 
These strategies were applied retrospectively to authentic forensic casework samples 
that were confirmed to contain NPS analogues at relatively low concentrations. All 
analytes of interest were detected using a combination of top-down and bottom-up 
screening strategies. Overall, these strategies offer a vendor-agnostic approach for the 
detection of NPS analogues that can be implemented immediately for samples of 
interest. 
 
 
 
 
